Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ventricular Outflow Obstruction

ClinicalTrials.gov lists 1,026 trials for Ventricular Outflow Obstruction or a narrower condition beneath it. Edwards Lifesciences has the most among industry and government lead sponsors, with 45.

MeSH D014694 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 9 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 22 Phase 2/3 Phase 2/3 8 Phase 3 Phase 3 29 Phase 4 Phase 4 54 Not applicable Not applicable 450 Observational Observational 452 Phase 1 Phase 1 9 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 22 Phase 2/3 Phase 2/3 8 Phase 3 Phase 3 29 Phase 4 Phase 4 54 Not applicable Not applicable 450 Observational Observational 452

Trials per phase (log scale)

1 more section with rows

7 of the 1,026 trials are tagged with Ventricular Outflow Obstruction itself; the rest are tagged with a narrower condition beneath it.

Get the Ventricular Outflow Obstruction report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ventricular Outflow Obstruction trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 76

1990: 1 trials (Observational 1) 1995: 1 trials (Observational 1) 2000: 1 trials (Phase 4 1) 2001: 2 trials (Observational 1, Phase 3 1) 2002: 3 trials (Observational 2, Phase 3 1) 2003: 6 trials (Observational 4, Not applicable 1, Phase 2 1) 2004: 1 trials (Observational 1) 2005: 5 trials (Observational 3, Phase 4 1, Phase 3 1) 2006: 13 trials (Observational 8, Not applicable 1, Phase 4 3, Phase 3 1) 2007: 19 trials (Observational 8, Not applicable 10, Phase 2/3 1) 2008: 12 trials (Observational 5, Not applicable 5, Phase 3 1, Phase 2 1) 2009: 17 trials (Observational 8, Not applicable 4, Phase 4 2, Phase 3 1, Phase 2/3 2) 2010: 22 trials (Observational 11, Not applicable 8, Phase 4 2, Phase 3 1) 2011: 24 trials (Observational 8, Not applicable 12, Phase 4 4) 2012: 48 trials (Observational 21, Not applicable 20, Phase 4 3, Phase 3 3, Phase 1/2 1) 2013: 42 trials (Observational 20, Not applicable 17, Phase 4 2, Phase 2 3) 2014: 50 trials (Observational 18, Not applicable 26, Phase 4 2, Phase 2 1, Phase 1 3) 2015: 41 trials (Observational 17, Not applicable 17, Phase 4 3, Phase 3 3, Phase 2 1) 2016: 68 trials (Observational 23, Not applicable 36, Phase 4 3, Phase 3 4, Phase 2 2) 2017: 63 trials (Observational 31, Not applicable 28, Phase 4 1, Phase 3 1, Phase 2 2) 2018: 58 trials (Observational 23, Not applicable 30, Phase 4 3, Phase 2 2) 2019: 62 trials (Observational 28, Not applicable 31, Phase 4 1, Phase 3 1, Phase 1 1) 2020: 68 trials (Observational 35, Not applicable 24, Phase 4 6, Phase 3 1, Phase 2 1, Phase 1 1) 2021: 57 trials (Observational 30, Not applicable 25, Phase 4 1, Phase 3 1) 2022: 54 trials (Observational 25, Not applicable 20, Phase 4 2, Phase 3 3, Phase 2/3 2, Phase 2 2) 2023: 76 trials (Observational 32, Not applicable 34, Phase 4 3, Phase 2/3 1, Phase 2 3, Phase 1 3) 2024: 76 trials (Observational 30, Not applicable 37, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 1) 2025: 74 trials (Observational 30, Not applicable 39, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 56
2025 74
2024 76
2023 76
2022 54
2021 57
2020 68
2019 62
2018 58
2017 63

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 71 trials starting in 2026 and about 73 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 101 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 541 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ventricular Outflow Obstruction trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 9
Phase 1/2 1
Phase 2 22
Phase 2/3 8
Phase 3 29
Phase 4 54
Not applicable 450
Observational 452
Expanded access 1

How many Ventricular Outflow Obstruction trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 62
Recruiting 181
Enrolling by invitation 17
Active, not recruiting 72
Completed 422

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ventricular Outflow Obstruction trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Edwards Lifesciences 45
Abbott Medical Devices 23
Medtronic Cardiovascular 17
Boston Scientific Corporation 16
Institut für Pharmakologie und Präventive Medizin 16

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Ventricular Outflow Obstruction? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Levosimendan 5
Rivaroxaban 4

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
EC Aspirin 7
Mavacamten Capsule 2 4
Apixaban IR 4
Blood Test 4
NaCl 0.9% NS 3

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Ventricular Outflow Obstruction trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other 1,781 16
Total 1,246 1
Atrioventricular block complete 1,006 18
Cardiac Conduction Disorders 943 5
Anaemias 755 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Ventricular Outflow Obstruction? (88)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Computed tomography derived predictors of left ventricular obstruction after TAVR. International journal of cardiology 2025 Yes
Transapical Beating-Heart Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy With Anomalous Papillary Muscle Insertion. Interdisciplinary cardiovascular and thoracic surgery 2025 Yes
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy With Residual Obstruction After Alcohol Septal Ablation. The Canadian journal of cardiology 2025 Yes
5-Year Outcomes of Anterior Mitral Leaflet Laceration to Prevent Outflow Obstruction. JACC. Cardiovascular interventions 2024 Yes
1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants. JACC. Cardiovascular interventions 2023 Yes

Showing 5 of 88 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages